z-logo
Premium
Linear epitopes in Onchocerca volvulus vaccine candidate proteins and excretory‐secretory proteins
Author(s) -
Lagatie Ole,
Verheyen Ann,
Van Dorst Bieke,
Batsa Debrah Linda,
Debrah Alex,
Stuyver Lieven J.
Publication year - 2018
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1111/pim.12587
Subject(s) - onchocerca volvulus , epitope , biology , proteome , onchocerciasis , immunology , antigen , virology , computational biology , bioinformatics
Summary In our previous study, a proteome‐wide screen was conducted to identify linear epitopes in this parasite's proteome, resulting in the discovery of three immunodominant motifs. Here, we investigated whether such antigenic peptides were found in proteins that were already known as vaccine candidates and excretome/secretome proteins for Onchocerca volvulus This approach led to the identification of 71 immunoreactive stretches in 46 proteins. A deep‐dive into the immunoreactivity profiles of eight vaccine candidates that were chosen as most promising candidates for further development ( Ov ‐ CPI ‐2, Ov ‐ ALT ‐1, Ov ‐ RAL ‐2, Ov ‐ ASP ‐1, Ov ‐103, Ov ‐ RBP ‐1, Ov ‐ CHI ‐1, and Ov ‐B20), resulted in the identification of a poly‐glutamine stretch in Ov ‐ RAL ‐2 that has properties for use as a serodiagnostic marker for O. volvulus infection. A peptide ELISA was developed, and the performance of this assay was evaluated. Based on this assessment, it was found that this assay has a sensitivity of 75.0% [95% CI : 64.9%‐83.5%] and a specificity of 98.5% [95% CI : 94.6%‐99.8%]. Furthermore, 8.7% reactivity in Asian parasite‐infected individuals (8 out of 92) was observed. Besides this identification of a linear epitope marker, the information on the presence of linear epitopes in vaccine candidate proteins might be useful in the study of vaccines for river blindness.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here